Next, they reported that human T cells from an IDH‐mutant glioma patient showed a concentration‐dependent reduction of IDH1 R132H‐specific IFN‐γ production, which was also validated in a transgenic mouse model generated by them. This evidence concerns the gene IDH2 and central nervous system cancer.